Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
RESEARCH TOOLSreports
ARQT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.99 - $16.20
Previous CloseN/A
Volume446.87K
Average Volume (3M)2.18M
Market Cap
$1.46B
Enterprise Value$1.03B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Feb 25, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding117,044,590
10 Day Avg. Volume2,704,249
30 Day Avg. Volume2,181,970
Standard Deviation0.27
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.56
Price to Cash Flow (P/CF)-10.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit18.91
Enterprise Value/Ebitda-6.33
Forecast
1Y Price Target
$19.60Price Target Upside50.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Financial PerformancePrescriptions for the Zoryve franchise are tracking 10.5% ahead of expectations.
Product AdoptionZoryve Cream 0.15% for atopic dermatitis reached new all-time highs for total and new prescriptions.
Bears Say
Competitive MarketKey risks include: commercial success is not assured since dermatology remains a highly competitive segment of the market.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $6.99 and its highest was $16.20 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Arcutis Biotherapeutics’s market cap is $1.46B.
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is Feb 25, 2025 which is in 4 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Nov 06, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.087.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is -0.26.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 117,044,590 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went up 7.66%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Currently, no hedge funds are holding shares in ARQT
---
Arcutis Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.60 (50.89% Upside)
$19.60 (50.89% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $585.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.67%
12-Months-Change
Fundamentals
Return on Equity
-192.31%
Trailing 12-Months
Asset Growth
49.29%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
---
ARQT Company Deck
---
ARQT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased significant growth in ZORYVE portfolio sales and gross-to-net improvements, indicating a strong financial performance. While there were some challenges, such as delays in Medicare Part D coverage and minor hurricane impacts, the overall outlook remains positive with strong cash management and expansion in Medicaid coverage.Read More>---
ARQT Stock 12 Month Forecast
Average Price Target
$19.60
▲(50.89% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Xoma
―
Aclaris Therapeutics
―
Kura Oncology
―
Journey Medical Corp
―
Best Analysts Covering ARQT
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
+33.15%
reiterated a buy rating last month
Copying Serge Belanger's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +33.15% per trade.
---